Selective Inhibition of HER2-Positive Breast Cancer Cells by the HIV Protease Inhibitor Nelfinavir | Zendy

Joong Sup Shim | Zendy; Rajini Rao | Zendy; Kristin Beebe | Zendy; Len Neckers | Zendy; Inkyu Han | Zendy; Rita Nahta | Zendy; Jun O. Liu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Selective Inhibition of HER2-Positive Breast Cancer Cells by the HIV Protease Inhibitor Nelfinavir

Author(s) -

Joong Sup Shim,

Rajini Rao,

Kristin Beebe,

Len Neckers,

Inkyu Han,

Rita Nahta,

Jun O. Liu

Publication year - 2012

Publication title -

jnci journal of the national cancer institute

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.797

H-Index - 356

eISSN - 1460-2105

pISSN - 0027-8874

DOI - 10.1093/jnci/djs396

Subject(s) - nelfinavir , breast cancer , medicine , protease inhibitor (pharmacology) , cancer , oncology , protease , human epidermal growth factor receptor 2 , trastuzumab , cancer research , human immunodeficiency virus (hiv) , immunology , biology , enzyme , viral load , antiretroviral therapy , biochemistry

Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is highly aggressive and has higher risk of recurrence than HER2-negative cancer. With few treatment options available, new drug targets specific for HER2-positive breast cancer are needed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research